Cos'è
In the last decades, survival rates of Multiple Myeloma have been brilliantly improved thanks to the introduction of novel agents: patients diagnosed after 2010 have had higher rates of novel therapy use and better survival outcomes compared with those of earlier years. Most relevant therapeutic advances over the past decades has been the introduction of novel therapies, such as immune modifying agents (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib), adopted with or without stem cell transplantation. Moreover, in the last few years, the MM therapeutic “toolbox” has improved further with the approval in new generation IMID (pomalidomide), the monoclonal antibodies, daratumumab and elotuzumab, as well as the newgeneration proteasome inhibitors, carfilzomib and ixazomib, waiting for introduction in daily practice of novel agents with new mechanism of action (Belantamab, CAR-T). At the same time, there is increasing understanding of MM tumor biology, creating the rationale for new combinations of drugs and new therapy development. Discovery of the associated cytogenetic abnormalities confirm the hypothesis that MM is a heterogeneous disease, suggesting that riskadapted therapies and individualizing treatment will further help improve patient management. The aim of this event is the discussion between international and national experts.
Tipo evento
Conferenza e Summit » Convegno
Parteciperanno
Bahlis Nizar (University of Calgary), Beilhack Andreas (University of Wuerzburg), Botta Cirino (Università degli Studi di Palermo), Bruno Benedetto (AOU Città della Salute e della Scienza - Torino), Buda Gabriele (Azienda Ospedaliero-Universitaria di Pisa), Cangini Delia (IRCCS IRST - Meldola, FC), Cavo Michele (Alma Mater Studiorum Università di Bologna), Ceccolini Michela (IRCCS IRST - Meldola, FC), Cellini Claudia (Ospedale S. Maria delle Croci - Ravenna), Cerchione Claudio (IRCCS IRST - Meldola, FC), Cortesi Sofia (IRCCS IRST - Meldola, FC), Derudas Daniele (Ospedale Armando Businco - Cagliari), De Santis Vanessa (Università di Bari Aldo Moro), Dimopoulos Meletios A. (University of Athens), Durie Brian (Cedars Sinai Medical Center - Los Angeles), Ghobrial Irene (Dana-Farber Cancer Institute / Harvard Medical School - Boston), Lee Hans Charles (Sarah Cannon Research Institute - Nashville), Lonial Sagar (Emory University School of Medicine - Atlanta), Lucchesi Alessandro (IRCCS IRST - Meldola, FC), Marchesini Matteo (IRCCS IRST - Meldola, FC), Martinelli Giovanni (Alma Mater Studiorum Università di Bologna), Mateos Maria Victoria (University of Salamanca), Montefusco Vittorio (IRCCS Istituto Nazionale dei Tumori - Milano), Moreau Philippe (University of Nantes), Musuraca Gerardo (IRCCS IRST - Meldola, FC), Nappi Davide (IRCCS IRST - Meldola, FC), Neri Paola (University of Calgary), Normanno Nicola (IRCCS IRST - Meldola, FC), Richardson Paul (Dana-Farber Cancer Institute / Harvard Medical School - Boston), Richter Joshua (Tisch Cancer Institute, Mount Sinai - New York), Romano Alessandra (Università degli Studi di Catania), Ronconi Sonia (IRCCS IRST - Meldola, FC), Rossi Alice (IRCCS IRST - Meldola, FC), Rotondo Francesco (Ospedale Infermi di Rimini), Schjesvold Fredrik (Oslo Myeloma Center), Solimando Antonio (Università di Bari Aldo Moro), Terragna Carolina (IRCCS Policlinico Sant’Orsola - Bologna), Zambello Renato (Scuola di Medicina e Chirurgia - Padova).
A chi si rivolge
Medical Surgeon (interdisciplinary area), Biologist, Pharmacist, TSLB, Nurse.
Dove
The Hive Hotel
Via Torino 6, Stazione Termini
00184 - Roma
Date e orari
Costi
Free, registration is compulsory.
Documenti
Contatti
Organizzato da
ProEventi - www.proeventi.it
Patrocinato da
- AIL
- AIOM
- GITMO
- SIE
- SIES
- SOHO Italy
Ultimo aggiornamento: 30 settembre 2025, 09:14